Aptinyx Inc logo

APTX - Aptinyx Inc Share Price

$2.68 -0.1  -3.2%

Last Trade - 16/04/21

Small Cap
Market Cap £129.8m
Enterprise Value £27.8m
Revenue £1.13m
Position in Universe 4618th / 6850
Unlock APTX Revenue
Relative Strength (%)
1m -24.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 9.79 4.96 6.57 3.67 1.56 12.2 -36.8%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AptinyxInc revenues decreased 57% to $1.6M. Net loss decreased 13%to $50.1M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Lower net loss reflects Research anddevelopment decrease of 27% to $30.6M (expense), Generaland administrative decrease of 5% to $11.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


APTX Revenue Unlock APTX Revenue

Net Income

APTX Net Income Unlock APTX Revenue

Normalised EPS

APTX Normalised EPS Unlock APTX Revenue

PE Ratio Range

APTX PE Ratio Range Unlock APTX Revenue

Dividend Yield Range

APTX Dividend Yield Range Unlock APTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
APTX EPS Forecasts Unlock APTX Revenue
Profile Summary

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 24, 2015
Public Since June 21, 2018
No. of Shareholders: 125
No. of Employees: 34
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 66,969,653
Free Float (0.0%)
Eligible for
APTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for APTX
Upcoming Events for APTX
Wednesday 28th April, 2021
Aptinyx Inc at Sachs Associates Neuroscience Innovation Forum (Virtual)
Wednesday 12th May, 2021 Estimate
Q1 2021 Aptinyx Inc Earnings Release
Thursday 20th May, 2021 Estimate
Aptinyx Inc Annual Shareholders Meeting
Thursday 27th May, 2021
Aptinyx Inc Annual Shareholders Meeting
Wednesday 11th August, 2021 Estimate
Q2 2021 Aptinyx Inc Earnings Release
Frequently Asked Questions for Aptinyx Inc
What is the Aptinyx Inc share price?

As of 16/04/21, shares in Aptinyx Inc are trading at $2.68, giving the company a market capitalisation of £129.8m. This share price information is delayed by 15 minutes.

How has the Aptinyx Inc share price performed this year?

Shares in Aptinyx Inc are currently trading at $2.68 and the price has moved by 16.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aptinyx Inc price has moved by -19.68% over the past year.

What are the analyst and broker recommendations for Aptinyx Inc?

Of the analysts with advisory recommendations for Aptinyx Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aptinyx Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aptinyx Inc next release its financial results?

Aptinyx Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Aptinyx Inc dividend yield?

Aptinyx Inc does not currently pay a dividend.

Does Aptinyx Inc pay a dividend?

Aptinyx Inc does not currently pay a dividend.

When does Aptinyx Inc next pay dividends?

Aptinyx Inc does not currently pay a dividend.

How do I buy Aptinyx Inc shares?

To buy shares in Aptinyx Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aptinyx Inc?

Shares in Aptinyx Inc are currently trading at $2.68, giving the company a market capitalisation of £129.8m.

Where are Aptinyx Inc shares listed? Where are Aptinyx Inc shares listed?

Here are the trading details for Aptinyx Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: APTX
What kind of share is Aptinyx Inc?

Based on an overall assessment of its quality, value and momentum, Aptinyx Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aptinyx Inc share price forecast 2021?

Shares in Aptinyx Inc are currently priced at $2.68. At that level they are trading at 0.294% discount to the analyst consensus target price of 0.00.

Analysts covering Aptinyx Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.078 for the next financial year.

How can I tell whether the Aptinyx Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptinyx Inc. Over the past six months, the relative strength of its shares against the market has been -40.96%. At the current price of $2.68, shares in Aptinyx Inc are trading at -25.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aptinyx Inc PE Ratio?

We were not able to find PE ratio data for Aptinyx Inc.

Who are the key directors of Aptinyx Inc?

Aptinyx Inc's management team is headed by:

Norbert Riedel - CEO
Ashish Khanna - CFO
Andrew Kidd - PRE
Patrick Enright - CHM
Elisha Gould - IND
Robert Hombach - IND
Adam Koppel - IND
Henry Gosebruch - IND
Rachel Sherman - IND
Who are the major shareholders of Aptinyx Inc?

Here are the top five shareholders of Aptinyx Inc based on the size of their shareholding:

Bain Capital Life Sciences Investors, LLC Investment Advisor
Percentage owned: 13.28% (8.89m shares)
Invus Public Equities Advisors, LLC Investment Advisor
Percentage owned: 9.13% (6.12m shares)
Adams Street Partners, LLC Private Equity
Percentage owned: 7.92% (5.31m shares)
Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 5.01% (3.36m shares)
New Leaf Venture Partners Venture Capital
Percentage owned: 4.91% (3.29m shares)
Similar to APTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.